Novo Nordisk NVO shares have rallied 11.2% over a month as investors regained confidence in the company's obesity growth ...

Eli Lilly LLY shares climbed to another all-time high of $1,235.56, pushing the drugmaker's market capitalization to roughly ...

Kailera Therapeutics' oral obesity drug helped patients lose up to 10.9% of their body weight at week 44 in a late-stage ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 7, Cantor Fitzgerald ...

Nxera Pharma, which has Cambridge, London and Tokyo facilities, is cashing in big time on a highly profitable collaboration ...

Developing protein-based ligands for G protein-coupled receptors (GPCRs) is challenging due to the structural complexity, dynamic flexibility and deeply recessed orthosteric binding pockets of these ...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural ...

Ever since humans began building, they’ve been building up. Throughout the millennia, our constructions have reached higher and higher into the sky, spurred by various motivations: religion, democracy ...

Proteins called β-arrestins regulate signalling through members of the G protein-coupled receptor (GPCR) superfamily. Small molecules that bind directly to the β-arrestins and inhibit their activities ...